What were we asked to look at?
What is the clinical effectiveness, cost effectiveness and safety of closed loop insulin systems and the artificial pancreas in the management of type I diabetes mellitus (T1DM)?
Why is this important?
There are currently 34,173 people living with type 1 diabetes in Scotland. The proportion of people with poorly controlled type 1 diabetes is over 31%. This is associated with increased morbidity and mortality risk. Access to technologies for treating diabetes is a key priority within the Scottish Government’s Diabetes Improvement Plan. Rapidly advancing diabetes technologies, such as the artificial pancreas or closed loop systems, have the potential to transform the lives of people living with type 1 diabetes. Patient demand for these technologies is increasing, with ≥70% of patients with type 1 diabetes expected to benefit from the artificial pancreas or closed loop systems in the future.
Scottish Diabetes Group